Abstract
Introduction A new method that corrects for time-dependent bias in standardized-uptake value ratios (SUVRs) was adapted and optimized for [11C]PiB (PiB) amyloid-beta (Aβ) PET, across low-to-high Aβ loads, relying only on PET data collected during the SUVR time-window. This modeling approach was evaluated in cross-sectional and longitudinal cohorts for earlier and shorter SUVR time-windows (30-45 min, 45-60 min) than commonly applied, to enable higher throughput imaging.
Methods The SUVR correction (SUVRc) approach was optimized and tested on separate cross-sectional (n=88), and longitudinal (36 participants, two time-points, 72 images) cohorts from the Harvard Aging Brain Study. The cross-sectional cohort spanned low, intermediate and high levels of cortical Aβ pathology and the longitudinal images included two cohorts with low (5-10%) and high levels (~40%) of Aβ change. SUVR and SUVRc were compared against SRTM DVR (0-60 min) to quantify Aβ burden through Pearson’s and Lin’s correlations, difference plots and longitudinal change.
Results The mean regional bias in PiB SUVR (5-15%, depending on time-window and Aβ burden) was significantly reduced to < 3% by SUVRc (corrected p < 0.05) in the cross-sectional cohorts for all time-windows, along with reductions in bias variability. SUVRc also showed higher Pearson’s correlation (r) and Lin’s concordance (LCC) with DVR across time-windows (r=0.98, LCC=0.99 at 30-45 min and 45-60 min) compared to uncorrected SUVR (r=0.96, LCC=0.95 at 30-45 min, r=0.97, LCC=0.92 at 45-60 min). Bland-Altman plots confirmed better agreement between SUVRc and DVR (mean bias at 30-45 min: 0.02 for SUVRc, 0.10 for SUVR; mean bias at 45-60 min: 0.01 for SUVRc, 0.17 for SUVR). Longitudinal DVR changes were more accurately represented by SUVRc, compared to uncorrected SUVR.
Conclusions SUVRc for [11C]PiB PET enables more accurate quantification of Aβ burden than SUVR in cross-sectional and longitudinal studies (relative to SRTM DVR), while enabling imaging at earlier and shorter time-windows. The improved accuracy would be beneficial in better quantifying amyloid re-emergence post anti-amyloid therapy and could be used for kinetic harmonization across time-windows and radiotracers.
Competing Interest Statement
K.A.J. has served as paid consultant for Janssen, Merck, Prothena, and Novartis. He has served as a site coinvestigator for Lilly, Eisai, Janssen, Cerveau, and Biogen. All other authors have no disclosures.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study procedures were approved by the Institutional Review Board for Massachusetts General Brigham. All participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Datasets used here can be accessed from Harvard Aging Brain Study Public Dataset by submitting an application through the Synapse HABS Repository and agreeing to the Data Use Agreement (DUA).
Funder Information Declared
